JP2008519080A - ナイアシン受容体部分的アゴニストを含む、潮紅および脂質関連障害を処置するための組成物 - Google Patents

ナイアシン受容体部分的アゴニストを含む、潮紅および脂質関連障害を処置するための組成物 Download PDF

Info

Publication number
JP2008519080A
JP2008519080A JP2007540384A JP2007540384A JP2008519080A JP 2008519080 A JP2008519080 A JP 2008519080A JP 2007540384 A JP2007540384 A JP 2007540384A JP 2007540384 A JP2007540384 A JP 2007540384A JP 2008519080 A JP2008519080 A JP 2008519080A
Authority
JP
Japan
Prior art keywords
niacin
analog
tetrazol
pyrazole
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007540384A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008519080A5 (enExample
Inventor
ドミニク ピー． ベーハン，
ダニエル ティー． コナリー，
ジェレミー リッチマン，
Original Assignee
アリーナ ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アリーナ ファーマシューティカルズ， インコーポレイテッド filed Critical アリーナ ファーマシューティカルズ， インコーポレイテッド
Publication of JP2008519080A publication Critical patent/JP2008519080A/ja
Publication of JP2008519080A5 publication Critical patent/JP2008519080A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007540384A 2004-11-05 2005-11-01 ナイアシン受容体部分的アゴニストを含む、潮紅および脂質関連障害を処置するための組成物 Pending JP2008519080A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62553604P 2004-11-05 2004-11-05
PCT/US2005/039560 WO2006052569A1 (en) 2004-11-05 2005-11-01 Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists

Publications (2)

Publication Number Publication Date
JP2008519080A true JP2008519080A (ja) 2008-06-05
JP2008519080A5 JP2008519080A5 (enExample) 2008-12-25

Family

ID=36046632

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007540384A Pending JP2008519080A (ja) 2004-11-05 2005-11-01 ナイアシン受容体部分的アゴニストを含む、潮紅および脂質関連障害を処置するための組成物

Country Status (7)

Country Link
US (1) US20080139628A1 (enExample)
EP (1) EP1811996A1 (enExample)
JP (1) JP2008519080A (enExample)
CN (1) CN101076331A (enExample)
AU (1) AU2005305086A1 (enExample)
CA (1) CA2584225A1 (enExample)
WO (1) WO2006052569A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
ATE440828T1 (de) 2003-11-21 2009-09-15 Arena Pharm Inc 4-oxo-4,5-dihydro-furan-2-carbonsäure und derivate und verfahren zur behandlung von stoffwechselerkrankungen mit diesen verbindungen
PL364348A1 (en) 2004-01-12 2005-07-25 PHARMENA Sp.z o.o. Application of quaternary pyridine salts as vessel protection agent
US20070021379A1 (en) 2005-07-11 2007-01-25 Pharmena North America Inc. Methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities
EP2099450A4 (en) * 2006-10-20 2011-01-26 Merck Sharp & Dohme AGONISTS OF THE NIACIN RECEPTOR, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND TREATMENT PROCEDURES
US8648103B2 (en) 2008-07-08 2014-02-11 Daiichi Sankyo Company, Limited Nitrogen-containing aromatic heterocyclyl compound
WO2011163612A1 (en) * 2010-06-24 2011-12-29 Trustees Of Tufts College Niacin mimetics, and methods of use thereof
US8450316B2 (en) 2010-06-24 2013-05-28 Trustees Of Tufts College Niacin mimetics, and methods of use thereof
CN103755637A (zh) * 2013-12-26 2014-04-30 平湖优康药物研发有限公司 一种医药中间体1,4,5,6-四氢-3-环戊并吡唑甲腈的合成工艺
US9456982B2 (en) 2014-05-18 2016-10-04 Be-Warm Llc Solid formulations of niacin to counteract cold extremities

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5268181A (en) * 1989-04-13 1993-12-07 Upsher-Smith Laboratories, Inc. Method of using niacin to control nocturnal cholesterol synthesis
AU5787996A (en) * 1995-04-19 1996-11-07 Lipoprotein Technologies, Inc. Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs
US6902902B2 (en) * 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
DE60327446D1 (de) * 2002-10-10 2009-06-10 Arena Pharm Inc 5-substituierte 2h-pyrazon-3-carbonsäure-derivate als antilipolytische mittel zur behandlung von stoffwechselstörungen, wie z.b. dyslipidemie
TWI258478B (en) * 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof

Also Published As

Publication number Publication date
EP1811996A1 (en) 2007-08-01
CA2584225A1 (en) 2006-05-18
AU2005305086A1 (en) 2006-05-18
WO2006052569A1 (en) 2006-05-18
US20080139628A1 (en) 2008-06-12
CN101076331A (zh) 2007-11-21

Similar Documents

Publication Publication Date Title
MX2007008376A (es) Terapia de combinacion para el tratamiento de diabetes y condiciones relacionadas con la misma, y para el tratamiento de las condiciones aminoradas por el aumento del nivel de glp-1 en sangre.
US20060122240A1 (en) Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof
RS50793B (sr) Korišćenje antagonista angiotenzin ii receptora, osobito telmisartana, u cilju povećanja insulinske senzitivnosti
MXPA96006404A (es) Composiciones farmaceuticas y metodos para formular trasnduccion de señales
JP2013082748A (ja) インスリン関連障害の処置のためのｇｐｒ４１およびその調節因子
JP2010163448A (ja) トリアゾール誘導体およびその代謝関連障害の処置方法
US20120208843A1 (en) Method of Using GPR35 to Identify Metabolic-Stabilizing Compounds
JP2008519080A (ja) ナイアシン受容体部分的アゴニストを含む、潮紅および脂質関連障害を処置するための組成物
JP2019532929A (ja) 化合物およびｐｄｅ４活性剤としてのそれらの使用
JP2018515594A (ja) トリアゾール誘導体およびｐｄｅ４活性化体としてその使用
JP2004515449A (ja) 第６ｇタンパク質共役型受容体の小分子調節物質
US20080161422A1 (en) Methods and Compositions for the Treatment of Lipid-Associated Disorders
JP2009051847A (ja) 代謝関連障害を処置するためのｇｐｒ４３およびその調節因子
US6420563B1 (en) Small molecule modulators of G protein-coupled receptor six
RS20060472A (sr) Oksidekahidronaftalen modulatori hm74
HK1100358B (en) Gpr41 and modulators thereof for the treatment of insulin-related disorders
EP1200427A2 (en) Small molecule modulators of g protein-coupled receptor six (gpr6)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081027

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110617

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110916

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110927

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111014

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111021

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111116

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120308